The Endocrine Profile of Bromocriptine: Its Application in Endocrine Diseases

Overview

Journal J Neural Transm

Specialties Neurology
Physiology

Date 1981 Jan 1

PMID 6455501

Citations 1

Authors

I Lancranjan

Affiliations

Soon will be listed here.

Abstract

Bromocriptine, a potent agonist at Dz receptors, was developed as a therapeutic agent for inhibiting prolactin (PRL) secretion in patients with hyperprolactinemia. Besides, its PRL-suppressive effect and a short-lasting growth hormone (GH)-releasing effect in normal volunteers, bromocriptine has no other endocrine effects in healthy subjects. On the other hand, bromocriptine lowers GH secretion in acromegalic patients and ACTH secretion in some patients with Cushing's disease or Nelson's syndrome. The paper reviews the endocrine actions of bromocriptine in man, in normal and pathological conditions, the bromocriptine's mechanism of action and its clinical applications in endocrinology.

Citing Articles

Development of a Rapid Insulin Assay by Homogenous Time-Resolved Fluorescence.

Farino Z, Morgenstern T, Vallaghe J, Gregor N, Donthamsetti P, Harris P PLoS One. 2016; 11(2):e0148684.

PMID: 26849707 PMC: 4743966. DOI: 10.1371/journal.pone.0148684.

References

Nillius S, Bergh T, Lundberg P, STAHLE J, Wide L . Regression of a prolactin-secreting pituitary tumor during long-term treatment with bromocriptine. Fertil Steril. 1978; 30(6):710-2. DOI: 10.1016/s0015-0282(16)43702-7. View

Miyal K, Onishi T, Hosokawa M, Ishibashi K, KUMAHARA Y . Inhibition of thyrotropin and prolactin secretions in primary hypothyroidism by 2-Br-alpha-ergocryptine. J Clin Endocrinol Metab. 1974; 39(2):391-4. DOI: 10.1210/jcem-39-2-391. View

Liuzzi A, Chiodini P, Botalla L, CREMASCOLI G, Muller E, Silvestrini F . Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration. J Clin Endocrinol Metab. 1974; 38(5):910-2. DOI: 10.1210/jcem-38-5-910. View

SHELESNYAK M . Ergotoxine inhibition of deciduoma formation and its reversal by progesterone. Am J Physiol. 1954; 179(2):301-4. DOI: 10.1152/ajplegacy.1954.179.2.301. View

Davies C, Jacobi J, LLOYD H, MEARES J . DNA synthesis and the secretion of prolactin and growth hormone by the pituitary gland of the male rat: effects of diethylstilboestrol and 2-bromo-alpha-ergocryptine methanesluphonate. J Endocrinol. 1974; 61(3):411-7. DOI: 10.1677/joe.0.0610411. View

FRANTZ A, Kleinberg D . Prolactin: evidence that it is separate from growth hormone in human blood. Science. 1970; 170(3959):745-7. DOI: 10.1126/science.170.3959.745. View

Bell R, Carruth A, Rosenberg R, Boyar R . Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease. J Clin Endocrinol Metab. 1978; 47(4):807-11. DOI: 10.1210/jcem-47-4-807. View

Muller E, Cocchi D, Panerai A, Gil-ad I, Locatelli V, Mantegazza P . Pituitary hormones and ergot alkaloids. Pharmacology. 1978; 16 Suppl 1:63-77. DOI: 10.1159/000136809. View

Fluckiger E, Wagner H . [2-Br-alpha-ergokryptin: influence on fertility and lactation in the rat]. Experientia. 1968; 24(11):1130-1. DOI: 10.1007/BF02147804. View

10.

Del Pozo E, Darragh A, Lancranjan I, Ebeling D, Burmeister P, Buhler F . Effect of bromocriptin on the endocrine system and fetal development. Clin Endocrinol (Oxf). 1977; 6 Suppl:47S-55S. DOI: 10.1111/j.1365-2265.1977.tb03338.x. View

11.

Del Pozo E, Brownell J . Prolactin. I. Mechanisms of control, peripheral actions and modification by drugs. Horm Res. 1979; 10(2-3):143-74. DOI: 10.1159/000178998. View

12.

Aronoff S, Daughaday W, Laws Jr E . Bromocriptine treatment of prolactinomas. N Engl J Med. 1979; 300(24):1391. DOI: 10.1056/NEJM197906143002411. View

13.

McGregor A, Scanlon M, Hall K, Cook D, Hall R . Reduction in size of a pituitary tumor by bromocriptine therapy. N Engl J Med. 1979; 300(6):291-3. DOI: 10.1056/NEJM197902083000606. View

14.

Caraceni T, Panerai A, Paratl E, Cocchi D, Muller E . Altered growth hormone and prolactin responses to dopaminergic stimulation in Huntington's chorea. J Clin Endocrinol Metab. 1977; 44(5):870-5. DOI: 10.1210/jcem-44-5-870. View

15.

Del Pozo E, Friesen H, Burmeister P . Endocrine profile of a specific prolactin inhibitor: Br-ergocryptine (CB 154). A preliminary report. Schweiz Med Wochenschr. 1973; 103(23):847-8. View

16.

Wass J, Moult P, Thorner M, Dacie J, Charlesworth M, Jones A . Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet. 1979; 2(8133):66-9. DOI: 10.1016/s0140-6736(79)90120-x. View

17.

Carey R, Thorner M, Ortt E . Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone. J Clin Invest. 1979; 63(4):727-35. PMC: 372008. DOI: 10.1172/JCI109356. View

18.

Bommer J, Ritz E, Del Pozo E, Bommer G . Improved sexual function in male haemodialysis patients on bromocriptine. Lancet. 1979; 2(8141):496-7. DOI: 10.1016/s0140-6736(79)91553-8. View

19.

Thorner M, Schran H, Evans W, Rogol A, Morris J, MacLeod R . A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic admknistration of bromocriptine. J Clin Endocrinol Metab. 1980; 50(6):1026-33. DOI: 10.1210/jcem-50-6-1026. View

20.

McGregor A, Scanlon M, Hall R, Hall K . Effects of bromocriptine on pituitary tumour size. Br Med J. 1979; 2(6192):700-3. PMC: 1596246. DOI: 10.1136/bmj.2.6192.700. View